← Ticker index
VRTX
Ticker
VRTX
Congressional Trades
28
by 7 members
Ticker disclosure brief
Congressional disclosure records for VRTX
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
David Taylor
SELL · 2026-01-29
Largest range
$15K – $50K
Jefferson Shreve
Longest observed gap
326d
Tommy Tuberville
Highest 30d vs SPY
9.4%
David Taylor
Purchase rows
12
43%
Sale rows
16
57%
Disclosed midpoint
$396K
range estimate
Unique Traders
7
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats1 · 4%
Republicans27 · 96%
Lobbying filings
all →- 2026-07-10$20KVERTEX PHARMACEUTICALS INCORPORATEDTax Reform - Restoring the Orphan Drug Tax Credit.
- 2026-07-09$60KVERTEX PHARMACEUTICALS INCORPORATEDIssues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy.
- 2026-04-20$80KVERTEX PHARMACEUTICALS INCORPORATEDFederal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues
- 2026-04-20$80KVERTEX PHARMACEUTICALS INCORPORATEDAccess to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
- 2026-04-20$60KVERTEX PHARMACEUTICALS INCORPORATEDMonitor issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process
- 2026-04-20$50KVERTEX PHARMACEUTICALS INCORPORATEDPatient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
- 2026-04-20$30KVERTEX PHARMACEUTICALS INCORPORATEDGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
- 2026-04-20$20KVERTEX PHARMACEUTICALS INCORPORATEDFY2027 Appropriations bills. FY2027 Appropriations bills.
- 2026-04-20$0VERTEX PHARMACEUTICALS INCORPORATED
- 2026-04-19$60KTIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS)
Loading trade analytics…
All Disclosed Trades
Page 2 · 3 of 28 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2024-05-03 | RTommy Tuberville | SELL | $1K – $15K | 42d | receipt → |
| 2019-02-04 | DJohn Reed | SELL | $1K – $15K | 1666dApparent delay | receipt → |
| 2022-10-06 | RTommy Tuberville | BUY | $1K – $15K | 326dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.